Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cerebral ischemia--challenges and perspectives].

J C Baron1

  • 1University of Cambridge, Department of Neurology and Stroke Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.

Therapie
|April 2, 2003
PubMed
Summary

Developing new treatments for acute ischaemic stroke is crucial, as current therapies like intravenous thrombolysis have limited eligibility. Despite promising preclinical results, neuroprotective agents have failed in clinical trials, necessitating a review of trial design and preclinical evaluation methods.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does frontal cortex hypometabolism in progressive supranuclear palsy result from subcortical dysfunction?

European journal of neurology·2013
Same author

Clues about the functional neuroanatomy of verbal working memory: a study of resting brain glucose metabolism in Parkinson's disease.

European journal of neurology·2013
Same author

Pharmacological therapies in post stroke recovery: recommendations for future clinical trials.

Journal of neurology·2013
Same author

A microPET study of the regional distribution of [11C]-PK11195 binding following temporary focal cerebral ischemia in the rat. Correlation with post mortem mapping of microglia activation.

NeuroImage·2011
Same author

Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat.

NeuroImage·2009
Same author

"Crossed cerebellar diaschisis" in human supratentorial brain infarction.

Transactions of the American Neurological Association·2009

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Medicine

Context:

  • Acute ischemic stroke treatment is limited, with intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) within 3 hours being the only proven therapy.
  • Less than 5% of stroke patients are eligible for rt-PA, highlighting a critical unmet need for alternative treatments.
  • Numerous neuroprotective agents have shown efficacy in preclinical animal models but have consistently failed in human clinical trials.

Purpose:

  • To review the potential reasons for the failure of neuroprotective agents in clinical trials for acute ischemic stroke.
  • To critically evaluate the methodologies of clinical trial design and preclinical testing for stroke therapeutics.
  • To propose solutions and suggest improvements for the development of effective neuroprotective drugs for ischemic stroke.

Summary:

  • Intravenous thrombolysis with rt-PA is the sole effective treatment for acute ischemic stroke, but its narrow therapeutic window and patient eligibility restrict its use.
  • Despite extensive research and promising preclinical data, all neuroprotective agents tested in randomized clinical trials have failed to demonstrate significant patient benefit.
  • This review examines the shortcomings in clinical trial design and preclinical evaluation that may explain the translational gap, proposing strategies to enhance future drug development.

Impact:

  • Identifying critical factors contributing to the failure of neuroprotective agents in clinical trials.
  • Providing a framework for improving the design of future clinical trials and preclinical studies for stroke therapies.
  • Guiding the development of more effective neuroprotective drugs to improve outcomes for the majority of acute ischemic stroke patients.

Related Experiment Videos